Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy    save search
Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S.
Published: 2023-02-07 (Crawled : 16:00) - biospace.com/
EXAS | $68.2 -0.54% 500K twitter stocktwits trandingview |
Health Technology
 | | O: -0.21% H: 0.0% C: 0.0%
sciences test therapy cancer
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
Published: 2023-02-07 (Crawled : 13:00) - biospace.com/
RCKT | $20.14 -4.1% 190K twitter stocktwits trandingview |
Health Technology
 | | O: -0.39% H: 0.0% C: 0.0%
fda pharmaceuticals designation disease for therapy rp-a501 rmat danon disease
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
Published: 2023-02-03 (Crawled : 14:20) - biospace.com/
MRK S | $106.95 1.2% 2.9M twitter stocktwits trandingview |
Health Technology
 | | O: -0.31% H: 0.0% C: 0.0%
keytruda for plus therapy
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
Published: 2023-02-02 (Crawled : 13:00) - biospace.com/
VSTM | $0.6862 -0.55% 490K twitter stocktwits trandingview |
Health Technology
 | | O: 5.61% H: 7.11% C: 4.14%
cancer therapy avutometinib ras pathway defactinib lgsoc program vs-6766
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
Published: 2023-01-31 (Crawled : 13:00) - biospace.com/
QURE | $22.24 -2.97% 62K twitter stocktwits trandingview |
Health Technology
 | | O: 0.97% H: 2.92% C: 1.72%
apb-102 global for als agreement therapy
Autologous Cell Therapy Market Report 2022: Sector to Reach $24.31 Billion by 2030 at a 19.4% CAGR
Published: 2023-01-30 (Crawled : 19:00) - prnewswire.com
GLW | News | $35.32 0.37% 1.8M twitter stocktwits trandingview |
Electronic Technology
 | | O: -0.74% H: 0.0% C: -4.89%
VCEL | $29.66 -4.75% 70K twitter stocktwits trandingview |
Health Technology
 | | O: -4.27% H: 1.89% C: 1.63%
report therapy market
Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
Published: 2023-01-30 (Crawled : 13:00) - biospace.com/
MRNA M | $165.25 -3.4% 1.4M twitter stocktwits trandingview |
Health Technology
 | | O: -2.73% H: 0.0% C: 0.0%
rna-1345 fda designation candidate for vaccine respiratory virus granted therapy
Cell & Gene Therapy Manufacturing Services Market worth $11.5 billion by 2027 - Exclusive Report by MarketsandMarkets™
Published: 2023-01-27 (Crawled : 15:20) - prnewswire.com
NINOY | $9.48 0 twitter stocktwits trandingview |
Manufacturing
 | Email alert Add to watchlist
NINOF | $9.37 0 twitter stocktwits trandingview |
Consumer Durables
 | Email alert Add to watchlist
services report therapy market
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
Published: 2023-01-26 (Crawled : 23:00) - biospace.com/
SANA | $4.505 -5.36% 160K twitter stocktwits trandingview |
| | O: 1.06% H: 1.05% C: -3.15%
sc291 fda clearance drug for application therapy
Cell Therapy Global Market Report 2022: Sector to Expand by 14.8% Annually Through 2033
Published: 2023-01-26 (Crawled : 19:00) - prnewswire.com
VCEL | $29.66 -4.75% 70K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
global report therapy market
Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause
Published: 2023-01-26 (Crawled : 14:00) - globenewswire.com
DARE | $1.235 2.92% 130K twitter stocktwits trandingview |
Health Technology
 | | O: 18.61% H: 2.19% C: -0.73%
for trial potential therapy bioscience publication hormone
CareCloud to Unveil Innovative EHR Therapy Platform at American Physical Therapy Association Meeting
Published: 2023-01-26 (Crawled : 14:00) - globenewswire.com
CCLD new | $3.42 6.8K twitter stocktwits trandingview |
Manufacturing
 | | O: 0.0% H: 0.0% C: -1.35%
meeting association therapy platform
Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA’s Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy
Published: 2023-01-26 (Crawled : 14:00) - globenewswire.com
SLDB | News M | $7.72 -0.52% 4.3K twitter stocktwits trandingview |
Health Technology
 | | O: 2.83% H: 0.94% C: 0.13%
RGNX | News | $23.435 -2.44% 85K twitter stocktwits trandingview |
Health Technology
 | | O: -0.43% H: 0.63% C: -0.69%
for application approval duchenne therapy publication
Scripps Health Radiation Therapy Centers Named Patient Safety Center of Excellence by Sun Nuclear
Published: 2023-01-26 (Crawled : 13:20) - prnewswire.com
MIR | News | $7.96 -1.85% 530K twitter stocktwits trandingview |
| | O: 2.09% H: 1.28% C: 0.64%
LEA | $140.63 -0.6% 190K twitter stocktwits trandingview |
Producer Manufacturing
 | | O: 2.8% H: 0.25% C: -0.34%
health nuclear therapy
Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
Published: 2023-01-25 (Crawled : 15:20) - biospace.com/
HOTH | News | $3.95 -8.14% 6.8M twitter stocktwits trandingview |
Health Technology
 | | O: 0.78% H: 0.0% C: 0.0%
for trial therapeutics therapy cancer growth
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
Published: 2023-01-25 (Crawled : 12:00) - biospace.com/
MRK S | $106.95 1.2% 2.9M twitter stocktwits trandingview |
Health Technology
 | | O: -0.56% H: 0.0% C: 0.0%
ynote-991 keytruda for trial plus therapy cancer
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
Published: 2023-01-24 (Crawled : 13:20) - biospace.com/
DBTX | $4.17 16.16% 210K twitter stocktwits trandingview |
Health Technology
 | | O: 7.82% H: 18.49% C: 15.32%
REGN M | $756.62 -1.73% 180K twitter stocktwits trandingview |
Health Technology
 | | O: 1.55% H: 0.18% C: -0.48%
candidate for application trial approval therapeutics therapy
Compression Therapy Market Size to Reach USD 4.77 Billion in 2030 | Emergen Research
Published: 2023-01-23 (Crawled : 18:00) - prnewswire.com
MMSI | $71.36 -0.35% 32K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
research therapy market
REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients
Published: 2023-01-23 (Crawled : 13:00) - biospace.com/
RGNX | News | $23.435 -2.44% 85K twitter stocktwits trandingview |
Health Technology
 | | O: -0.88% H: 1.37% C: 0.09%
rgx-202 candidate active for trial duchenne therapy
Market Forecasts for Immuno-Oncology Diagnostics 2023: Sector Represents a Revolution in Cancer Therapy
Published: 2023-01-20 (Crawled : 22:00) - prnewswire.com
ABT | $110.4 -1.42% 1.3M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
ANPCY | $3.545 0 twitter stocktwits trandingview |
Manufacturing
 | Email alert Add to watchlist
BIO | $471.46 -1.15% 20K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
TXG | $46.53 -3.7% 300K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
MDLS | $ 0% twitter stocktwits trandingview |
n/a
 | Email alert Add to watchlist
NVTA | $2.39 -3.63% 5.4M twitter stocktwits trandingview |
Health Services
 | Email alert Add to watchlist
TMO | $582.1 -0.18% 430K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
BDX S | $250.455 -1.08% 340K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
ANPCF | $0.52 twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
CSTL S | $26.845 0.09% 53K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
ICLR | $239.76 -0.89% 130K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
BIOC | $0.514 45K twitter stocktwits trandingview |
Health Services
 | Email alert Add to watchlist
NH | $3.9 4.5% 4.8K twitter stocktwits trandingview |
Technology Services
 | Email alert Add to watchlist
MLAB G | $181.51 -0.95% 25K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
for diagnostics therapy cancer market
Gainers vs Losers
52% 48%

Top 10 Gainers
DGLY | News | $5.43 1722.15% 150K twitter stocktwits trandingview |
Electronic Technology
CELZ | $1.11 114.58% 120M twitter stocktwits trandingview |

GFAI | $0.481 40.85% 60M twitter stocktwits trandingview |

KPRX | News | $6.17 35.6% 14M twitter stocktwits trandingview |
Manufacturing
PRFX | $0.65 30.0% 13M twitter stocktwits trandingview |
Health Technology
WETG | $0.514 25.37% 11M twitter stocktwits trandingview |

AVRO | $1.07 22.64% 540K twitter stocktwits trandingview |
Health Technology
BBLG | $0.3799 20.76% 740K twitter stocktwits trandingview |
n/a
MSGM P 2 d | $15.78 19.73% 5.1M twitter stocktwits trandingview |

THCH | $4.995 18.93% 550K twitter stocktwits trandingview |
n/a
Your saved searches
Save your searches and get alerts when important news are released.